Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc (NASDAQ: NCNA) is a clinical-stage biopharmaceutical company focused on developing ProTide-based cancer therapies, and the NCNA news feed highlights the company’s ongoing clinical, regulatory, and corporate developments. NuCana reports that it is applying its proprietary ProTide technology to transform widely used nucleoside analog chemotherapy agents into new medicines designed to overcome key limitations of these drugs and generate higher concentrations of active anti-cancer metabolites in cancer cells.
News about NuCana frequently centers on its two lead product candidates, NUC-7738 and NUC-3373. Coverage includes updates from the NuTide:701 Phase 1/2 study of NUC-7738 in advanced solid tumors and in combination with pembrolizumab in patients with melanoma, including PD-1 inhibitor-resistant metastatic melanoma. Articles also report on data from the NuTide:303 Phase 1b/2 study of NUC-3373 in combination with pembrolizumab for advanced solid tumors and with docetaxel for lung cancer, as well as preclinical findings that explore immunogenic effects and synergy with PD-1 inhibitors.
Investors following NCNA news can expect announcements on clinical data presented at major oncology meetings, such as European Society for Medical Oncology congresses, publications in scientific journals and preprint servers, and updates on intellectual property, including composition-of-matter patents for NUC-7738. The news flow also covers financial results, capital-raising activities such as at-the-market offerings and warrant transactions, Nasdaq listing and ADS ratio changes, and leadership or board changes reported in Form 6-K filings.
This page aggregates these company-issued press releases and related disclosures so readers can monitor NuCana’s progress in oncology drug development, track milestones for NUC-7738 and NUC-3373, and review structural updates that may affect the NCNA stock listing and capital structure.
NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress 2024, showcasing encouraging results for NUC-7738 in combination with pembrolizumab for metastatic melanoma patients refractory to or relapsed on prior PD-1 inhibitor therapy. The study, involving 12 patients, demonstrated a 75% disease control rate, including two partial responses. Notably, 7 out of 12 patients achieved progression-free survival exceeding five months, which is significant for this patient population. The combination therapy also exhibited a favorable safety profile. NUC-7738's mechanism of action, targeting multiple aspects of the tumor microenvironment, is believed to sensitize PD-1 resistant tumors to rechallenge with PD-1 inhibitors.
NuCana plc (NASDAQ: NCNA) announced the discontinuation of its NuTide:323 study following a pre-planned analysis and recommendation from the Steering Committee. The study, which aimed to develop NUC-3373 as a replacement for 5-FU in second-line colorectal cancer treatment, was unlikely to achieve its primary objective of superior Progression Free Survival compared to the control arm.
Despite this setback, NuCana remains committed to its ongoing development programs. The company will continue with the NuTide:701 and NuTide:303 studies, focusing on NUC-7738 in combination with pembrolizumab. Encouraging data from these studies will be presented at the ESMO Annual Conference in September 2024.
NuCana plc (NASDAQ: NCNA) reported Q2 2024 financial results and provided a business update. Key points include:
- Cash and cash equivalents of £11.6 million as of June 30, 2024
- Net loss of £7.0 million for Q2 2024
- Loss per ordinary share of £0.12
The company is advancing clinical programs for NUC-3373 (ProTide transformation of 5-FU) and NUC-7738 (ProTide transformation of 3'-deoxyadenosine). Multiple data readouts are expected in H2 2024, including updates from Phase 2 studies in colorectal cancer and melanoma. NuCana anticipates its cash runway to extend into Q1 2025.
NuCana (Nasdaq: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will present at the Jefferies Global Healthcare Conference on June 6, 2024, at 12:30 PM EDT in New York, NY. The presentation will be webcast live and made available for replay in the Investors section of the NuCana website.
NuCana (Nasdaq: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will present at TD Cowen’s 5th Annual Oncology Innovation Summit on May 28, 2024, at 8:30 AM EDT. This virtual event will offer insights related to ASCO & EHA. The live webcast and replay will be accessible through the Investors section of NuCana's website.
NuCana (NASDAQ: NCNA) has released its financial results for Q1 2024, ending March 31, 2024. The company reported a net loss of £6.8 million, an improvement from £7.9 million in Q1 2023. Cash and cash equivalents stood at £12.9 million, down from £17.2 million at the end of 2023. Loss per share was £0.13, reduced from £0.15 in the comparable period.
Key developments include the full enrollment of a Phase 2 study involving 182 colorectal cancer patients and encouraging results from NUC-7738 combined with pembrolizumab in patients resistant to PD-1 inhibitors. NuCana's clinical programs, including NUC-3373 and NUC-7738, are on track for significant data readouts in 2024. The company expects its cash runway to extend into Q1 2025.
NuCana aims to announce multiple clinical data points in 2024, focusing on metastatic colorectal cancer and melanoma treatments.
NuCana plc (NASDAQ: NCNA) has announced that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Stock Market. The company had previously been notified of non-compliance due to its closing bid price falling below $1.00 for 30 consecutive business days. However, after maintaining a minimum closing bid price of $1.00 or more for 10 consecutive business days, NuCana has now met the requirement, as confirmed by a Notification Letter from Nasdaq.
Summary not available.
Summary not available.
Summary not available.